Quarterly report [Sections 13 or 15(d)]

Significant Strategic Collaborations (Details Narrative)

v3.25.2
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 17, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue   $ 589,897 $ 726,404 $ 1,183,158 $ 1,237,221  
Research and development expenses   656,557 933,771 1,535,586 1,878,092  
Advance payment and included within prepaid expenses and other current assets   573,854   573,854   $ 421,954
Recognized revenue   589,897 726,404 1,183,158 1,237,221  
Collaborative Agreements [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Recognized revenue   0 0 0 0  
Takeda [Member] | Royalty Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue   600,000 $ 700,000 1,200,000 $ 1,200,000  
Catalent Pharma Solutions [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses       2,700,000    
Advance payment and included within prepaid expenses and other current assets   300,000   300,000   28,000
Liability and included in accrued expenses and other current liabilities   200,000   200,000   100,000
Other assets           300,000
Scripps Research [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses $ 900,000          
Scripps Research [Member] | Scripps Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses       1,400,000    
Accrued expenses   100,000   100,000    
Prepaid expenses and other           $ 400,000
University Of Virginia [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses       400,000    
Advance payment and included within prepaid expenses and other current assets   100,000   100,000    
Advance payments   $ 0   $ 0